Innovation1 Biotech Inc.

IVBT

US39809D2018

Investment Holding Companies

Market Closed - OTC Markets Other stock markets 09:31:07 2024-04-19 am EDT			5-day change	1st Jan Change
0.0008 ^USD	-96.36%		0.00%	-99.07%

Jan. 17	Innovation1 Biotech Inc. Reports Earnings Results for the Full Year Ended August 31, 2023	CI
2023	Innovation1 Biotech Inc. announced that it has received $0.15 million in funding	CI

Innovation1 Biotech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2022

July 14, 2022 at 04:43 pm EDT

Innovation1 Biotech Inc. reported earnings results for the third quarter and nine months ended May 31, 2022. For the third quarter, the company reported net loss was USD 1.61 million compared to net income of USD 0.796156 million a year ago. Basic loss per share from continuing operations was USD 0.09 compared to basic earnings per share from continuing operations of USD 4.22 a year ago.
For the nine months, net loss was USD 3.63 million compared to net income of USD 1.12 million a year ago. Basic loss per share from continuing operations was USD 0.27 compared to basic earnings per share from continuing operations of USD 5.94 a year ago.

Latest news about Innovation1 Biotech Inc.

Innovation1 Biotech Inc. Reports Earnings Results for the Full Year Ended August 31, 2023	Jan. 17	CI
Innovation1 Biotech Inc. announced that it has received $0.15 million in funding	Dec. 05	CI
Innovation1 Biotech Inc. announced that it has received $0.02 million in funding	Oct. 31	CI
Innovation1 Biotech Inc. announced that it has received $0.02 million in funding	23-10-10	CI
Innovation1 Biotech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2023	23-09-13	CI
Innovation1 Biotech Inc. announced that it has received $0.066891 million in funding	23-08-31	CI
Innovation1 Biotech Inc. Announces Resignation of Patrick Morris as Chairman of the Board	23-08-11	CI
Innovation1 Biotech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended February 28, 2023	23-05-30	CI
Innovation1 Biotech Inc. Announces Resignation of Jeffrey Kraws as a Director	23-04-24	CI
Innovation1 Biotech Inc. announced that it expects to receive $0.28 million in funding from Cavalry Fund I Management, LLC, Lincoln Park Capital, LLC, L1 Capital Pty. Limited	23-04-12	CI
Innovation1 Biotech Inc. Reports Earnings Results for the First Quarter Ended November 30, 2022	23-01-17	CI
Innovation1 Biotech Inc. announced that it has received $0.3 million in funding from Cavalry Fund I Management, LLC, L1 Capital Pty. Limited, Lincoln Park Capital, LLC	22-12-26	CI
Innovation1 Biotech Inc. Reports Earnings Results for the Full Year Ended August 31, 2022	22-12-15	CI
Innovation1 Biotech Inc. Auditor Raises 'Going Concern' Doubt	22-12-14	CI
Innovation1 Biotech Inc. Announces Board Appointments	22-12-12	CI
Innovation1 Biotech Inc. announced that it expects to receive $0.3 million in funding from Cavalry Fund I Management, LLC, L1 Capital Pty. Limited, Lincoln Park Capital, LLC	22-11-28	CI
Innovation1 Biotech Inc. Announces the Resignation of Andrew Salzman as Chief Science Officer	22-11-17	CI
Ingenius Biotech S.L. acquired All Of The Assets Relating to Mioxal from Innovation1 Biotech Inc. for $0.1 million.	22-11-13	CI
Innovation1 Biotech Inc. Announces Resignation of Andrew Salzman	22-10-25	CI
Innovation1 Biotech Inc. Appoints Frederick E. Pierce, Ii to Its Board of Directors	22-09-15	CI
Innovation1 Biotech Inc. Announces Filing of Patent Application for Novel Combination Therapy Targeting Addiction	22-08-18	CI
Innovation1 Biotech Inc. Appoints Andrew L. Salzman, M.D., to Its Board of Directors	22-08-11	CI
Innovation1 Biotech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2022	22-07-14	CI
Innovation1 Biotech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended February 28, 2022	22-04-15	CI
Innovation1 Biotech, Inc. Announces Director Changes	22-04-08	CI

Chart Innovation1 Biotech Inc.

Duration

Period

More charts

Company Profile

Innovation1 Biotech Inc. is a shell company. The Company has no operations and is evaluating a number of strategic alternatives including, but not limited to, seeking to acquire a new business in the United States, including potentially by means of a reverse merger with an operating entity. The Company has no sources of revenue.

Sector

Investment Holding Companies

More about the company

Income Statement Evolution

More financial data

Sector Shell Companies

	1st Jan change	Capi.
INNOVATION1 BIOTECH INC.	-99.07%	17.98K
TRUMP MEDIA & TECHNOLOGY GROUP CORP.	+137.37%	5.68B
SCREAMING EAGLE ACQUISITION CORP.	+1.89%	1.01B
CHURCHILL CAPITAL CORP VII	+2.19%	982M
APPLE ISPORTS GROUP, INC.	+41.91%	872M
PERELLA WEINBERG PARTNERS	+25.27%	819M
ARES ACQUISITION CORPORATION II	+1.68%	663M
E7 GROUP	+0.54%	610M
DA ZHONG TRADING GROUP HOLDING COMPANY	-.--%	600M
ALTC ACQUISITION CORP.	+21.31%	552M